Overview
- Researchers demonstrated that a cfRNA model predicted early-onset preeclampsia with 83% sensitivity and 90% specificity on average 18 weeks before clinical diagnosis.
- The test also forecasted late-onset preeclampsia on average 14.9 weeks before onset by identifying a distinct molecular signature.
- Transcriptomic analyses revealed widespread multi-organ molecular changes in early-onset cases and localized immune and liver pathway alterations in late-onset preeclampsia.
- The study analyzed cfRNA from 548 plasma samples collected from 216 pregnant people at multiple time points in the first and second trimesters and at diagnosis.
- With the manuscript under peer review, the research team has begun prospective clinical trials and submitted regulatory applications to integrate cfRNA screening into standard prenatal care.